Monoclonal Antibodies Market, by Source (Human, Chimeric, Murine, and Humanized), by Application (Cancer, Autoimmune Disease, Hematological Disease, Infectious Disease, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online P

Monoclonal Antibodies Market, by Source (Human, Chimeric, Murine, and Humanized), by Application (Cancer, Autoimmune Disease, Hematological Disease, Infectious Disease, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. For instance, in 2017, the U.S. Food & Drug Administration (FDA) approved Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients suffering from multiple myeloma, who have received two prior therapies. These factors are expected to support growth of the market over the forecast period.
Market Dynamics
Rising incidence of cancer and other chronic diseases is a major factor that is expected to boost the monoclonal antibodies market growth over the forecast period. According to GLOBOCAN, in 2018, an estimated 43.6% new cases of breast cancer were registered in Asia Pacific. Also, according to the American Cancer Society, 2017, cancer was the second most common cause of death in the U.S., which accounted for around 1 out of every 4 deaths.
Market players are focused on combining monoclonal antibodies with other therapies such as chemotherapy drugs, which is expected to assist the market growth over the forecast period. For instance, combination of nivolumab and ipilimumab for the treatment of intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma was approved in the U.S. in 2018 and in January 2021 in Europe.
Moreover, efforts of manufacturers to increase number of indications (oncology) for monoclonal antibodies is further expected to boost the market growth over the forecast period. For instance, in June 2018, the U.S. Food & Drug Administration (FDA) expanded the indication of pembrolizumab (Keytruda) to include recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Key features of the study:
This report provides in-depth analysis of the global monoclonal antibodies market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global monoclonal antibodies market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc., AbbVie Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future launches, market expansion, and marketing tactics
The global monoclonal antibodies market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global monoclonal antibodies market
Detailed Segmentation:
Global Monoclonal Antibodies Market, By Source:
Human
Chimeric
Murine
Humanized
Global Monoclonal Antibodies Market, By Application:
Cancer
Autoimmune Disease
Hematological Disease
Infectious Disease
Others
Global Monoclonal Antibodies Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Monoclonal Antibodies Market, By Region:
North America
By Source:
Human
Chimeric
Murine
Humanized
By Application:
Cancer
Autoimmune Disease
Hematological Disease
Infectious Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Source:
Human
Chimeric
Murine
Humanized
By Application:
Cancer
Autoimmune Disease
Hematological Disease
Infectious Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Source:
Human
Chimeric
Murine
Humanized
By Application:
Cancer
Autoimmune Disease
Hematological Disease
Infectious Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Source:
Human
Chimeric
Murine
Humanized
By Application:
Cancer
Autoimmune Disease
Hematological Disease
Infectious Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Source:
Human
Chimeric
Murine
Humanized
By Application:
Cancer
Autoimmune Disease
Hematological Disease
Infectious Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Source:
Human
Chimeric
Murine
Humanized
By Application:
Cancer
Autoimmune Disease
Hematological Disease
Infectious Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Pfizer Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Novartis AG
Bayer AG
Sanofi S.A.
Hoffmann-La Roche AG
Eli Lilly and Co.
Merck & Co., Inc.
GlaxoSmithKline Plc.
AbbVie Inc.
Bristol-Myers Squibb
Regeneron Pharmaceuticals Inc.
“*” marked represents similar segmentation in other categories in the respective section.